Press Release
Category Added in a WPeMatico Campaign
-
Cision PR Newswire6 November 2025WhiteFiber, Inc. Announces Details for Q3 2025 Earnings Conference Call
NEW YORK, Nov. 6, 2025 /PRNewswire/ — WhiteFiber, Inc. (NASDAQ: WYFI), a leading provider of AI infrastructure and HPC solutions,…
Read More » -
Cision PR Newswire6 November 2025Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants…
Read More » -
Cision PR Newswire6 November 2025DeFi Technologies Reports an Arbitrage Trade of $3.2 Million by DeFi Alpha
Arbitrage Trade Execution: DeFi Alpha, DeFi Technologies’ specialized arbitrage trading desk, generated a one-time return of approximately $3.2 million from an…
Read More » -
Cision PR Newswire6 November 2025Nova Reports Record Third Quarter 2025 Financial Results
REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ — Nova (NASDAQ: NVMI) today announced financial results for the third quarter, the three-month…
Read More » -
Cision PR Newswire6 November 2025
Continuum Recovery Center of Colorado Selects the Janus Contingency Management Platform to Strengthen Addiction Treatment Services
BOSTON, Nov. 6, 2025 /PRNewswire/ — Continuum Recovery Center of Colorado (CRC), a leading Denver-based outpatient addiction treatment provider, announced…
Read More » -
Cision PR Newswire6 November 2025Generate Capital Raises over $1 Billion to Expand Infrastructure Credit Solutions
SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Generate Capital (“Generate”), a leading sustainable infrastructure investment platform, today announced it has raised in…
Read More » -
Cision PR Newswire6 November 2025Callan Publishes Asset Manager Sustainable Investment Practices Study
Findings show how asset managers integrate sustainability factors into their investment processes SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Callan, a…
Read More » -
Cision PR Newswire6 November 2025MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
-First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX…
Read More » -
Cision PR Newswire6 November 2025Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
DOVER, Del., Nov. 6, 2025 /PRNewswire/ — Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and…
Read More » -
Cision PR Newswire6 November 2025ATDev Joins $41 Million ARPA-H Initiative to Build the Future of Robotic Mobility and Independence
PITTSBURGH, Nov. 6, 2025 /PRNewswire/ — Assistive Technology Development, Inc. (ATDev) announced today that it is a subcontractor for the…
Read More »